Attached files
| file | filename |
|---|---|
| EX-31.1 - CERTIFICATION BY CEO - CytoDyn Inc. | d249747dex311.htm |
| EX-21.1 - SUBSIDIARIES - CytoDyn Inc. | d249747dex211.htm |
| EX-31.2 - CERTIFICATION BY CFO - CytoDyn Inc. | d249747dex312.htm |
| EX-10.10 - AMENDMENT NUMBER 5 TO THE CLINICAL TRIAL AGREEMENT - CytoDyn Inc. | d249747dex1010.htm |
| 10-K - FORM 10-K - CytoDyn Inc. | d249747d10k.htm |
| EX-32.2 - CERTIFICATION OF CFO PURSUANT TO 18. U.S.C. SECTION 1350 AS ADOPTED - 906 - CytoDyn Inc. | d249747dex322.htm |
Exhibit 32.1
Certification of the Chief Executive Officer
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of CytoDyn Inc. (the “Company”) on Form 10-K for the fiscal year ended May 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-K “), I, Kenneth J. Van Ness, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Form 10-K fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 3, 2011
| /s/ Kenneth J. Van Ness |
| Kenneth J. Van Ness |
| President and Chief Executive Officer |